Settore concorsuale: 05/D1
Settore Scientifico Disciplinare: BIO/09
Dipartimento di Biologia e biotecnologie "Charles Darwin", Facoltà di Scienze Matematiche Fisiche e Naturali
CODICE CONCORSO 2023PAE011; D.R. n. 778/2023 del 31.03.2023

ALL. B

Decreto Rettore Università di Roma "La Sapienza" n 778/2023 del 31.03.2023

in conformità a quanto prescritto dall'art. 4 del Codice in materia di protezione dei dati personali e dall'art. 26 del D. Lgs. 14 marzo 2013, n. 33.

CURRICULUM VITAE

MOZZETTA Chiara

Part I – General Information

Researcher Identifiers	ORCiD ID: 0002-7147-7266; Scopus Author ID: 22934763900

Part II – Education

November 2013	II level Master in Preclinical and Clinical Drug Development. Catholic University, Medical School, Rome, Italy. Pharmatrain centre of excellence.
February 2009	PhD in Genetics and Molecular Biology. University "Sapienza" of Rome, Italy.
November 2004	Master degree in Biological Sciences, (110/110 cum laude) University "Sapienza" of Rome, Italy.

Part III - Qualifications

November 2020	National Scientific Qualification for Associate Professor (Abilitazione Scientifica Nazionale, ASN, II Fascia). Academic Discipline: Physiology (05/D1-BIO/09) (05/E2 – BIO/11); Histology (05/H2- BIO/17).
April 2018	National Scientific Qualification for Associate Professor (Abilitazione Scientifica Nazionale, ASN, II Fascia). Academic Discipline: Molecular Biology (05/E2 – BIO/11); Experimental Biology (05/F1- BIO/13).

Part IV – Academic appointments

Since Jan 2023	"**Primo Ricercatore**" at Institute of Molecular Biology and Pathology (IBPM) - National Research Council (CNR).
28/12/18-31/12/22	"**Ricercatore III livello**" at Institute of Molecular Biology and Pathology (IBPM) - National Research Council (CNR).
01/05/16-27/12/18	"**RTD-A**" ("chiamata diretta") at University Sapienza of Rome, Dept. of Biology and Biotechnology "C. Darwin". Italy, Rome.

Part V - Research experiences and positions

12/2018-present	**Principal Investigator** at Institute of Molecular Biology and Pathology (IBPM) - National Research Council (CNR). Epigenetic regulation of muscle progenitor cells in skeletal muscle regeneration and disease.

05/2016-27/12/2018	**Principal Investigator** at University Sapienza of Rome, Dept. of Biology and Biotechnology "C. Darwin". Italy, Rome. Epigenetic regulation of muscle progenitor cells in skeletal muscle regeneration and disease.
08/2013- 04/2016	**Research Associate (A/R Senior)**, National Research Council (CNR) of Italy, Rome. Institute of Cell Biology and Neurobiology (IBCN). **Dr. Chiara Lanzuolo lab**, Research project: Epigenetic basis of Laminopathies: cross-talk between nuclear lamins and Polycomb group proteins.
12/2010- 07/2013	**Post-doc** at UMR7216 CNRS/University Paris Cité, Paris (France), ***Dr. Slimane Ait-Si-Ali lab***. Research Project: Epigenetic regulation of gene transcription. Role of histone methyltransferases in the regulation of embryonic and adult stem cells fate. *Fellowships:* ***FRM and EMBO long-term.***
02/2009 - 11/2010	**Post-doc** at Fondazione S. Lucia (FSL), Rome (Italy), ***Dr. Pier Lorenzo Puri lab***. Research Project: Identification and characterization of muscle interstitial stem cells as a target of HDAC inhibitors in the treatment of muscular dystrophy. *Fellowships:* ***AFM post-doc fellowships (1 year + renewal)***.
05/2009 - 08/2009	**Visiting Research Scientist** at Sanford-Burnham for Medical Research, La Jolla (CA, USA).
01/2005 - 01/2009	**Post-graduate and PhD training**, ***Dr Pier Lorenzo Puri*** l***ab*** at Dulbecco Telethon Institute c/o European Brain Research Institute/S. Lucia, Rome (Italy). Research projects: Study of chromatin signalling in muscle stem cells during skeletal muscle regeneration. *Fellowships/contracts:* ***Parent project co.co.co. and AFM PhD fellowships.***
02/2008 - 03/2008	**Visiting PhD fellow**, ***Dr. David Sassoon*** lab at Myology Institute, University Pierre et Marie Curie, Paris (France).
10/2006 – 01/2007	**Visiting PhD student** at Sanford-Burnham for Medical Research, La Jolla (CA, USA).
10/2002 – 12/2004	**Undergraduate fellow, *Prof. Gabriella Augusti-Tocco lab at*** the Department of Cellular and Developmental Biology, University "La Sapienza" of Rome (Italy). Research project: Role of Acetylcholine in the regulation of neuronal development.

Part VI- Research activity

The research in my lab aims to dissect the epigenetic mechanisms governing muscle progenitor cells' fate determination. We are interested in studying how histone modifying enzymes control stem cells' alternative transcriptional programs and fates. We aim to reveal how these epigenetic players control skeletal muscle differentiation/regeneration, with the goal to understand how these processes are deregulated in muscle disorders, such as muscular dystrophies and malignancies of muscular origin as rhabdomyosarcomas

Keywords: *Muscle stem cells, skeletal muscle differentiation, fibro-adipogenic progenitors, epigenetics, chromatin, methyltransferases, muscular dystrophy, rhabdomyosarcoma, neuromuscular disorders*

Part VII - Funding as Principal Investigator (PI)

Secured funds**: 1,9 million EUR/since 2015.**

2023-2028 **AIRC (Italian Association for Cancer Research) Investigator Grant:** Aberrant chromatin-nuclear lamina interactions in stromal cells as underlying mechanism of rhabdomyosarcoma initiation. Project Id # 27532.
630000 eur /5 years.

2022-2025 **Muscular Dystrophy Association (MDA):** Assessing the role of Fibro-Adipogenic Progenitors in EDMD. Project Id # 964058.
279300 $/3 years. From October 2022

2020 **Sarcoma Foundation of america (SFA):** Unwinding new therapeutic opportunities in rhabdomyosarcoma: the role of RNA helicase DDX5. Project Id #SFA 20-02.
50000 $/1 year.

2019-2020 **AFM-Telethon:** Deciphering the role of Prdm16-mediated H3K9 methylation in the control of Fibro-Adipogenic Progenitors identity and skeletal muscle repair. Project Id # 22489.
82000 eur/2 years**.**

2017 **Contract with IRBM** for a third-party collaboration**.**
60000 eur/1 year

2016/2017 **CNCCS (Consortium National Collection of Compounds and Chemical Screening Center):** Targeting Histone Methyltransferases: in quest of pharmacological therapies for rare muscle diseases.
40000 eur/2016; **70000 eur**/2017.

2018 **Integrated projects "LIFE 2020" POR FESR LAZIO 2014:** "RESEARCH – Riposizionamento E Sviluppo Economico di Attività di Ricerca su Composti HDACi". In partnership with IRBM (Pomezia, Italy).
277489 eur/18 months

2017-2021 **MyFIRST AIRC grant, Italian Association for Cancer Research (AIRC):** Histone H3K9 Methyltransferase G9a in the patho-epigenetic deregulation of rhabdomyosarcoma. Project Id #18993.
222600 eur/3 years

2016-2020 **Scientific Independence of Young Researcher (SIR), Italian Ministry of University and Research:** Role of Prdm16 and histone H3 lysine 9 methyltransferases G9a/GLP in the epigenetic regulation of Fibro-Adipogenic Progenitors fate choice in dystrophic muscles. Project Id # RBSI14QMG0.
459800 eur/3 years

Part VIII- Teaching and Tutoring Experiences

2017- 2022 **Lecturer** for the course "Animal Physiology" (6 CFU; Academic Discipline BIO/09), BSc in Environmental Sciences (L-32), Faculty of Sciences University Sapienza of Rome.

2019-present **Lecturer** for the course "Molecular Medicine" for Sapienza School for Advanced Studies (SSAS), University Sapienza of Rome.

2016-present **MS students' supervisor** c/o MSs "Neurobiology" and "Genetics and Molecular Biology" courses, University Sapienza of Rome.

2016- 2021 **PhD students' supervisor** c/o PhD course "Cell and Developmental Biology", University Sapienza of Rome.

Part IX - Institutional responsibilities

2018-present **Faculty committee**, PhD course "Cell and Developmental Biology", University Sapienza of Rome.

2017-2022 **Member**, Committee for **Quality Assurance Management**, BSc Environmental Sciences (L-32), Faculty of Sciences University "Sapienza" of Rome

2016- to date **Member** of the **examining committee** for "General Physiology" for the BSc in Biological Sciences (L-13) and "Animal Physiology" for Natural Sciences (L-32) and Environmental Sciences (L-32), Faculty of Sciences University "Sapienza" of Rome.

Part X - Fellowships/Awards

Part X – A Fellowships

Dr. Ait-Si-Ali lab (UMR7216 CNRS, Paris):

9/2011-8/2013 **EMBO Long-term post-doc fellowship** (#LT-1283_2010*). Project title: "Epigenetic regulation of muscle stem cells proliferation and differentiation: cooperation between Polycomb/H3K27 methylation and H3K9 methylation pathways"*.

1/2011-8/2011 **FRM (Fondation pour la Recherche Médicale**), post-doc fellowship (prematurely interrupted to start EMBO-LTF). *Project title: "Epigenetic regulation of muscle stem cells proliferation and differentiation: cooperation between Polycomb/H3K27 methylation and H3K9 methylation pathways"*

Dr. Puri lab (Rome/San Diego):

2010 **Post-doc fellowship** granted by **AFM** (Association Française contre les Myopathies) (#14863). *Project title: "*Characterization of deacetylase inhibitors-responsive population of muscle progenitor cells in dystrophic mice".

2009 **Post-doc fellowship** granted by **AFM** (Association Française contre les Myopathies) (#13952). *Project title: "*Characterization of deacetylase inhibitors-responsive population of muscle progenitor cells in dystrophic mice".

2008 **PhD fellowship** granted by **AFM** (Association Française contre les Myopathies) (#13323). *Project title: "*Pharmacological manipulation of p38 chromatin-signaling in satellite cells to promote muscle regeneration".

Part X – B AWARDS

2014 Molecular Cell paper (Mozzetta et al., 2014) selected by the Faculty of 1000 amongst the most relevant papers in Biology and Medicine (https://f1000.com/prime/718228225#)

2010 Cell Stem Cell paper (Palacios*, Mozzetta* et al, 2010; equal 1st authors) selected by the Faculty of 1000 amongst the most relevant papers in Biology and Medicine https://f1000.com/prime/5601964#

Part XI – Appointments to scientific board and committees

2023 Panel member of the scientific committee for the French National Research Agency (Agence Nationale de la Recherche, ANR).

Part XII – Editorial-reviewer activities

Part XII A – Reviewer activities

Since 2015 Invited reviewer of research articles for Nature Communications, Developmental Cell, EMBO reports, FASEB journal, Stem Cell Reports, The Journal of Physiology, Scientific reports, Cellular and Molecular Life Sciences, Epigenomics, Medical Epigenetics; Frontiers Physiology.

Since 2015 Invited Grants reviewer for AFM (Association Française contre les Myopathies), Muscular Dystrophy UK, French National Research Agency (ANR, France), German Research Foundation, Fondazione Cariparo, National Science Center (Poland).

Part XII A – Editorial activities

2018 Lead Guest Editor of the Research Topic "Epigenetic Regulation of Stem Cell Plasticity in Tissue Regeneration and Disease" in Frontiers Cell & Developmental Biology.

Part XIII- Meetings and Presentations

Part XIII-A **Invited** Presentations

20-23 Oct 2022 **Interuniversity Institute of Myology (IIM), XIX Annual Meeting**. Pathogenesis and therapies of neuromuscular diseases. Assisi (Italy). **Keynote speaker**. Title: Epigenetic reprogramming of muscle-resident mesenchymal cells as a therapeutic approach in muscular dystrophies

24-29 July 2022 **FASEB conference:** The Skeletal Muscle Stem Cells and Regeneration Conference, New Orleans (USA) Title: Heterochromatin-nuclear lamina interactions regulate cell fate plasticity during skeletal muscle repair

23 June 2022 **Epigenetic seminars at Université Paris Cité** (France). Title: Heterochromatin-nuclear lamina interactions regulate cell fate plasticity during skeletal muscle repair

22 June 2022 **XXV London Myology Forum.** Title: Heterochromatin-nuclear lamina interactions regulate cell fate plasticity during skeletal muscle repair. Virtual

14-19 Nov 2021 **Frontiers in Myogenesis Conference,** Herradura (Costa Rica). Title: Chromatin-nuclear lamina interactions regulate fibro-adipogenic progenitors identity (*not attended for Covid19 pandemic restrictions).*

30 Sept 2021 **Berlin Muscle Club**. Title: Heterochromatin-nuclear lamina interactions regulate cell fate plasticity during skeletal muscle repair. Virtual

24 May 2021 **Epigenetics Monday Seminars,** University of Trento, CIBIO (Italy).Title: Heterochromatin-nuclear lamina interactions regulate cell fate plasticity during skeletal muscle repair. Virtual.

24 Mar 2017 **Seminar series "The Nucleus and the control of gene expression", PhD School in Biomedical Sciences and Biotechnology**. **University of Udine**, (Italy). Title: Epigenetic regulation of muscle resident stem cells during skeletal muscle regeneration and disease.

26-27 Sept 2016 **1st EMBL/Sapienza PhD meeting "Chromatin & Epigenetics", Rome**, (Italy). Title: Epigenetic regulation of muscle resident stem cells during skeletal muscle regeneration and disease.

Part XIII-B **Selected** for an oral presentation.

24-27 June 2020 **ISSCR (International Society for Stem Cell Research) 2020 Virtual meeting.** Prdm16-mediated H3K9 methylation controls fibro- adipogenic progenitors plasticity and mouse skeletal muscle repair

23-28 Sept 2019 **Frontiers in Myogenesis: Skeletal Muscle: Development, Regeneration and Disease,** San Jose **(**Costa Rica)**.** H3K9 methylation controls Fibro-Adipogenic Progenitors identity and skeletal muscle repair.

19-21 Sept 2018	**69th Congress of the Italian Physiological Society**. Florence (Italy). Title: Inhibition of Histone H3 Lysine 9 methyltransferases promotes skeletal muscle repair and morphological recovery of dystrophic muscles
20-22 Jun 2018	**SIBBM 2018 Frontiers in Molecular Biology.** Sapienza University, Rome (Italy). Title: H3K9 methylation controls Fibro-Adipogenic Progenitors identity and skeletal muscle repair.
10-13 Oct 2013	**Interuniversity Institute of Myology (IIM), X Annual Meeting.** Borgo San Luigi a Monteriggioni (Siena, Italy). Title: The histone h3 lysine 9 methyltransferases G9a/GLP regulate polycomb repressive complex 2-mediated gene silencing.
13-18 May 2007	**Gordon Research Conference: Myogenesis.** Castelvecchio Pascoli (Lucca, Italy). Title: Targeting the chromatin of myogenic progenitors to control muscle regeneration

Part XIV– Publications

For each publication journal IF (in the year of publication; source JCR), number of citations (source: Scopus) and press/media release (if any) are shown.

Part XIV–A Publications as **first** and/or **last/corresponding-author**

1. **Mozzetta C.** Epigenetic regulation of stem cells. ***Encyclopedia of Cell Biology*** 2nd edition Editor(s): Ralph A. Bradshaw, Gerald W. Hart, Philip D. Stah.l Volume 6, 2023, Pages 84-98. Doi: 10.1016/B978-0-12-821618-7.00258-3. ISBN: 9780128216248. *Invited Book Chapter*

   #Citations: **N/A**; IF:**N/A**

2. Gualtieri A., Bianconi V. Licursi V., Renzini A., Pieroni L., **Mozzetta C.** The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth. ***Cell Reports,*** 2022, *40*, Aug 30th. Doi.org/10.1016/j.celrep.2022.111267.
   #Citations: **1**; IF: **9,9950**

3. De Stefano M.E., Ferretti V, **Mozzetta C**. Synaptic alterations as a neurodevelopmental trait of Duchenne muscular dystrophy. ***Neurobiology of Disease***. 2022 Jun 15;168:105718. doi: 10.1016/j.nbd.2022.105718.

   #Citations: **4**; IF: **7,0460**

4. Bianconi V. and **Mozzetta C.** Epigenetic control of muscle stem cells: time for a new dimension. ***Trends in Genetics***, *2022 Jan 22:S0168-9525(22)00001-4. doi: 10.1016/j.tig.2022.01.001. Invited review.*

   #Citations: **2**; IF: **11,8210**

5. Macino M., Biferali B., Cipriano A., Ballarino M, **Mozzetta C.** Targeting the Expression of Long Noncoding RNAs in Murine Satellite Cells from Single Myofibers. ***Bio Protoc.*** 2021 Nov 5;11(21):e4209.

   #Citations: **0**; IF: **N/A**

6. Biferali B., Bianconi V., Fernandez Perez D., Pöhle Kronawitter S., Marullo F., Maggio R., Santini T., Polverino F., Biagioni S., Summa V., Toniatti C., Pasini D., Stricker S., Di Fabio R., Chiacchiera F., Peruzzi G., **Mozzetta C.** Prdm16-mediated H3K9 methylation controls Fibro-Adipogenic Progenitors identity during skeletal muscle repair. ***Science Advances 2021, 7(23), eabd9371***

   #Citations: **14**; IF: **14,98**

7. Cipriano A., Macino M., Bonaiuto G., Santini T., Biferali B., Peruzzi G., Colantoni A., **Mozzetta C[§],** Ballarino M[§]. Epigenetic regulation of Wnt7b expression by the cis-acting long noncoding RNA lnc-Rewind in muscle stem cells. ***Elife*** *2021, 10, pp. 1–25, e54782*.[§] co-corresponding.

#Citations: **16**; IF: **9,7130**

8. Pegoli G., Lucini F., **Mozzetta C[§],** Lanzuolo C[§]**,** Single Myofiber Isolation and Culture from a Murine Model of Emery-Dreifuss Muscular Dystrophy in Early Post-Natal Development. ***Jove*** 2020; doi:10.3791/61516. [§]co-corresponding

#Citations: **2**; IF: **1,3550**

9. Bianchi A.*, **Mozzetta C.*,** Pegoli G., Lucini F., Valsoni S., Rosti V., Petrini C., Cortesi A., Gregoretti F., Antonelli L., Oliva G., De Bardi M., Rizzi R., Bodega B., Pasini D., Ferrari F., Bearzi C., Lanzuolo C. Polycomb dysfunctional transcriptional repression contributes to Lamin A/C dependent muscular dystrophy. ***Journal of Clinical Investigation.*** 2020 doi:10.1172/JCI128161 * equal.

#Citations: **21**; IF: **14,8080**

10. Chiacchiera F, Morey L, **Mozzetta C.** Editorial: Epigenetic Regulation of Stem Cell Plasticity in Tissue Regeneration and Disease. ***Front Cell Dev Biol*** 2020 doi: 10.3389/fcell.2020.00082.

#Citations: **4**; IF: **6,6840**

11. **Mozzetta C[§]** Tedesco FS. Challenging the "chromatin hypothesis" of cardiac laminopathies with LMNA mutant iPS cells. ***J Cell Biol****.* 2019 doi: 10.1083/jcb.201907166. [§] corresponding author

#Citations: **6**; IF: 8,8110

12. Biferali B., Proietti D., **Mozzetta C.** [§]and Madaro L.[§]. Fibro-Adipogenic Progenitors (FAPs) cross-talk in skeletal muscle: the social network. ***Frontiers Physiology*** *2019; doi: 10.3389/fphys.2019.01074.*[§] co-corresponding

#Citations: **102**; IF: **3,3670**

13. Biferali B and **Mozzetta C.** Epigenetic Regulation of Muscle Stem Cells During Skeletal Muscle Regeneration and Disease. Elsevier volume: **Epigenetics and Regeneration.** 2019; doi:10.1016/B978-0-12-814879-2.00013-3. Invited book chapter.

#Citations: **1**; IF: **N/A**

14. **Mozzetta C**. Isolation and culture of muscle stem cells. ***Methods Mol Biol***. 2016; 1480:311-22. doi: 10.1007/978-1-4939-6380-5_27.

#Citations: **4**; IF: **N/A**

15. **Mozzetta C[§],** Boyarchuk E, Pontis J, Ait-Si-Ali S[§]. Sound of Silence: The properties and functions of repressive lysine methyltransferases**.** ***Nature Review Molecular Cell Biology***. 2015 Aug;16(8):499-513. doi: 10.1038/nrm4029. Review. [§] corresponding author.

#Citations: **132**; IF: **38.602**

16. **Mozzetta C[§]**, Pontis J, Ait-Si-Ali S[§]. Functional crosstalks between lysine methyltransferases on histone substrates: the case of G9a/GLP and PRC2. Invited review ***Antioxidant & Redox Signaling, special issue on Epigenetics***. 2014 Nov 3. [§] corresponding author

#Citations: **26**; IF: **7.407**

17. Consalvi S, Saccone V, **Mozzetta C§.** Histone Deacetylase Inhibitors (HDACi): the potential of an epigenetic treatment for Duchenne Muscular Dystrophy. **Epigenomics**. Invited review. 2014;6(5):547-60. doi: 10.2217/epi.14.36. **''**. §corresponding author

#Citations: **22**; IF: **4.649**

18. **Mozzetta C §,** Pontis J, Fritsch L, Robin P, Portoso M, Proux C, Margueron R, Ait-Si-Ali S§ (2014). The Histone H3 Lysine 9 Methyltransferases G9a and GLP Regulate Polycomb Repressive Complex 2-Mediated Gene Silencing. ***Molecular Cell***. Jan 23;53(2):277-89. doi: 10.1016/j.molcel.2013.12.005. Epub 2014 Jan 2. § corresponding author

#Citations: **189**; IF: **14.018**

Press release: Research highlight entitled "Methyltransferases 'talk' at histone H3" on Nature Review Molecular Cell Biology doi: 10.1038/n rm3746

19. **Mozzetta C**, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. (2013). Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. ***EMBO Molecular Medicine***, 5, 626–39. doi:10.1002/emmm.201202096.

#Citations: **152**; IF: **8.245**

20. Corsetti V*, **Mozzetta C*,** Biagioni S, Augusti Tocco G, Tata AM. The mechanisms and possible sites of acetylcholine release during chick primary sensory neuron differentiation. ***Life Sci.*** (2012) Oct 22;91(15-16):783-8. doi: 10.1016/j.lfs.2012.08.026. * equal contribution

#Citations: **12**; IF: **2.555**

21. **Mozzetta, C.,** Consalvi, S., Saccone, V., Forcales, S. V, Puri, P. L., & Palacios, D. Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. ***Cell cycle*** (2011) 10, 191–198. doi:10.4161/cc.10.2.14441.

#Citations: **34**; IF: **5.359**

22. Palacios, D.*, **Mozzetta, C.*,** Consalvi, S., Caretti, G., Saccone, V., Proserpio, V., Marquez SV., Valente S., Mai A., Forcale SV., Sartorelli V., Puri, P. L. (2010). TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. **Cell Stem Cell**, 7, 455–469. doi:10.1016/j.stem.2010.08.013. * equal contribution

#Citations: **321**; IF**: 25.943**

Press release: Preview article "The Yin and Yang of Polycomb Repression in Regenerating Muscle" (DOI 10.1016/j.stem.2010.09.005) on the same issue of Cell Stem Cell.

23. **Mozzetta, C**., Minetti, G., & Puri, P. L. (2009). Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy. ***The international journal of biochemistry & cell biology***, 41, 701–710. doi:10.1016/j.biocel.2008.08.033.

#Citations: **35**; IF: **4.887**

Part XIV–A Publications as **co-author**

24. Dattilo D., Di Timoteo G., Setti A., Giuliani A., Peruzzi G., Beltran M, Centron-Broco A., Mariani D., **Mozzetta C**., Bozzoni I. The m6A reader YTHDC1 and the RNA helicase DDX5 promote the production of rhabdomyosarcoma-enriched circRNAs. ***Nature Communication*** 2023 Apr 5;14(1):1898. doi: v.

#Citations: **0**; IF: **17,6940**

25. Randazzo P, Sinisi R, Gornati D, Bertuolo S, Bencheva L, De Matteo M, Nibbio M, Monteagudo E, Turcano L, Bianconi V, Peruzzi G, Summa V, Bresciani A, **Mozzetta C**, Di Fabio R. Identification and in vitro characterization of a new series of potent and highly selective G9a inhibitors as novel anti-fibroadipogenic agents. ***Bioorg Med Chem Lett.*** 2022 Sep 15;72:128858. doi: 10.1016/j.bmcl.2022.128858. Epub 2022 Jun 16.

#Citations: **1**; IF: **2,94**

26. Morotti M., Garofalo S., Cocozza G., Antonangeli F., Bianconi V., **Mozzetta C**., De Stefano M.E., Capitani R., Wulff H., Limatola C., Catalano M., Grassi F. Muscle damage in dystrophic mdx mice is I nfluenced by the activity of Ca2+-activated KCa3.1 channels. ***Life***. 2022 12, 538. https://doi.org/10.3390/life12040538.

#Citations: **1**; IF: **3,2530**

27. Cirigliano A, Amelina A, Biferali B, Macone A, **Mozzetta C**, Bianchi MM, Mori M, Botta B, Pick E, Negri R, Rinaldi T. Statins interfere with the attachment of *S. cerevisiae* mtDNA to the inner mitochondrial membrane. ***J Enzyme Inhib Med*** Chem. 2020; doi: 10.1080/14756366.2019.1687461

#Citations: **6**; IF: **5,0510**

28. Cesarini E, **Mozzetta C**, Marullo F, Gregoretti F, Gargiulo A, Columbaro M, Cortesi A, Antonelli L, Di Pelino S, Squarzoni S, Palacios D, Zippo A, Bodega B, Oliva G, Lanzuolo C. Lamin A/C sustains PcG protein architecture, maintaining transcriptional repression at target genes. ***J Cell Biol.*** 2015 Nov 9;211(3):533-51. doi: 10.1083/jcb.201504035.

#Citations: **76**; IF: **8.717**

29. Saccone V, Consalvi S, Giordani L, **Mozzetta C**, Ryan T, Madaro L, Rojas Munoz A, Bruneau B, Fasanaro P, Termanini A, Barozzi I, Mercola M, Minucci S, Puri P.L. (2014) HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibroadipogenic progenitors in dystrophic muscles. ***Genes & Development***, Apr 15;28(8):841-57. doi: 10.1101/gad.234468.113.

#Citations: **106**; IF: **10.798**

Press release: Comment "**Dystrophic muscle environment induces changes in cell plasticity"** on the same issue of Genes & Development. http://www.genesdev.org/cgi/doi/10.1101/gad.241182.114**.**

30. Consalvi S, **Mozzetta C,** Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V. (2013). Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. ***Molecular medicine*** (Cambridge, Mass.), 19, 79–87. doi:10.2119/molmed.2013.00011

#Citations: **93**; IF: **4.824**

31. Stojic L, Jasencakova Z, Prezioso C, Stützer A, Bodega B, Pasini D, Klingberg R, **Mozzetta C**, Margueron R, Puri PL, Schwarzer D, Helin K, Fischle W, Orlando V. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. ***Epigenetics Chromatin*** (2011) Sep 5;4:16. doi: 10.1186/1756-8935-4-16.

#Citations: **99**; IF: **4.462**

32. Consalvi, S., Saccone, V., Giordani, L., Minetti, G., **Mozzetta, C**., & Puri, P. L. Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases. ***Molecular medicine*** Cambridge Mass, (2011). 17, 457–465. doi:10.2119/molmed.2011.00049.

#Citations: **55**; IF: **3.757**

33. Colussi C, Gurtner A, Rosati J, Illi B, Ragone G, Piaggio G, Moggio M, Lamperti C, D'Angelo G, Clementi E, Minetti G, **Mozzetta C,** Antonini A, Capogrossi MC, Puri PL, Gaetano C. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. ***The FASEB journal*** (2009) 23, 2131–2141. doi:10.1096/fj.08-115618

#Citations: **60**; IF: **6.401**

34. Salani M, Anelli T, Tocco GA, Lucarini E, **Mozzetta C,** Poiana G, Tata AM, Biagioni S. Acetylcholine-induced neuronal differentiation: muscarinic receptor activation regulates EGR-1 and REST expression in neuroblastoma cells. ***Journal of neurochemistry***, (2009) 108, 821–834. doi:10.1111/j.1471-4159.2008.05829.

#Citations: **21**; IF: **3.999**

35. Colussi C, **Mozzetta C,** Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, Minetti G, Martelli F, Piaggio G, Gallinari P, Steinkuhler C, Clementi E, Dell'Aversana C, Altucci L, Mai A, Capogrossi MC, Puri PL, Gaetano C. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment***. PNAS***, (2008) 105, 19183–19187. doi:10.1073/pnas.0805514105

#Citations: **209**; IF: **9.380**

36. Serra C, Palacios D, **Mozzetta C,** Forcales SV, Morantte I, Ripani M, Jones DR, Du K, Jhala US, Simone C, Puri PL. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. ***Molecular Cell,*** (2007) 28, 200–213. doi:10.1016/j.molcel.2007.08.021

#Citations: **164**; IF: **13.156**

37. Minetti GC, Colussi C, Adami R, Serra C, **Mozzetta C,** Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, Illi B, Gallinari P, Steinkühler C, Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C, Puri PL. Functional and *morphological* recovery of dystrophic muscles in mice treated with deacetyase inhibitors. **Nature Medicine** (2006) Oct;12(10):1147-50. Epub 2006 Sep 17.

#Citations: **262**; IF: **28.588**

38. Bandi, E., Bernareggi, A., Grandolfo, M., **Mozzetta, C.,** Augusti-Tocco, G., Ruzzier, F., & Lorenzon, P. (2005). Autocrine activation of nicotinic acetylcholine receptors contributes to Ca2+

spikes in mouse myotubes during myogenesis. ***The Journal of physiology***, 568, 171–180. doi:10.1113/jphysiol.2005.091439
#Citations: **29**; IF: **4.272**

Part XV – Summary of Scientific Achievements

Papers [international]: **36** (35 among articles, reviews, short surveys; and 1 editorial)
Books chapter [scientific]: **3.**
Funds as PI: **1,9 million EUR/**since 2015

Total Impact factor: **332,586** (last 10 years 2013-2023: ***219,83***) (source JCR)
Total Citations: **2283** (last 10 years 2013-2023: ***980***) (source Scopus)
Average Citations per Product: **60** (last 10 years 2013-2023: ***39***) (source Scopus)
Hirsch (H) index: **21** (last 10 years 2013-2023: ***12***) (source Scopus)
Normalized H index*: **1,16** (H index (21)/years since first publication (18))

Luogo e data, Roma, 16/05/2023

Firma